511 related articles for article (PubMed ID: 25497312)
1. Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer.
Neijzen R; Wong MQ; Gill N; Wang H; Karim T; Anantha M; Strutt D; Waterhouse D; Bally MB; Tai IT; Ng SS; Yapp DT
J Control Release; 2015 Feb; 199():72-83. PubMed ID: 25497312
[TBL] [Abstract][Full Text] [Related]
2. Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.
Verreault M; Wehbe M; Strutt D; Masin D; Anantha M; Walker D; Chu F; Backstrom I; Kalra J; Waterhouse D; Yapp DT; Bally MB
J Control Release; 2015 Dec; 220(Pt A):348-357. PubMed ID: 26528901
[TBL] [Abstract][Full Text] [Related]
3. Treatment of colorectal cancer using a combination of liposomal irinotecan (Irinophore C™) and 5-fluorouracil.
Hare JI; Neijzen RW; Anantha M; Dos Santos N; Harasym N; Webb MS; Allen TM; Bally MB; Waterhouse DN
PLoS One; 2013; 8(4):e62349. PubMed ID: 23626804
[TBL] [Abstract][Full Text] [Related]
4. Irinophore C™, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model.
Verreault M; Strutt D; Masin D; Anantha M; Waterhouse D; Yapp DT; Bally MB
J Control Release; 2012 Feb; 158(1):34-43. PubMed ID: 22001870
[TBL] [Abstract][Full Text] [Related]
5. Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine.
Verreault M; Strutt D; Masin D; Anantha M; Yung A; Kozlowski P; Waterhouse D; Bally MB; Yapp DT
BMC Cancer; 2011 Apr; 11():124. PubMed ID: 21477311
[TBL] [Abstract][Full Text] [Related]
6. Irinophore C, a novel nanoformulation of irinotecan, alters tumor vascular function and enhances the distribution of 5-fluorouracil and doxorubicin.
Baker JH; Lam J; Kyle AH; Sy J; Oliver T; Co SJ; Dragowska WH; Ramsay E; Anantha M; Ruth TJ; Adam MJ; Yung A; Kozlowski P; Minchinton AI; Ng SS; Bally MB; Yapp DT
Clin Cancer Res; 2008 Nov; 14(22):7260-71. PubMed ID: 19010842
[TBL] [Abstract][Full Text] [Related]
7. Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities.
Waterhouse DN; Sutherland BW; Santos ND; Masin D; Osooly M; Strutt D; Ostlund C; Anantha M; Harasym N; Manisali I; Wehbe M; Bally MB; Webb MS
Invest New Drugs; 2014 Dec; 32(6):1071-82. PubMed ID: 25064374
[TBL] [Abstract][Full Text] [Related]
8. Irinophore C: a liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors.
Ramsay EC; Anantha M; Zastre J; Meijs M; Zonderhuis J; Strutt D; Webb MS; Waterhouse D; Bally MB
Clin Cancer Res; 2008 Feb; 14(4):1208-17. PubMed ID: 18281556
[TBL] [Abstract][Full Text] [Related]
9. Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil.
Nakajima TE; Yasunaga M; Kano Y; Koizumi F; Kato K; Hamaguchi T; Yamada Y; Shirao K; Shimada Y; Matsumura Y
Int J Cancer; 2008 May; 122(9):2148-53. PubMed ID: 18196580
[TBL] [Abstract][Full Text] [Related]
10. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice.
Allegrini G; Goulette FA; Darnowski JW; Calabresi P
Cancer Chemother Pharmacol; 2004 Mar; 53(3):261-6. PubMed ID: 14658007
[TBL] [Abstract][Full Text] [Related]
11. Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion.
Kalra AV; Kim J; Klinz SG; Paz N; Cain J; Drummond DC; Nielsen UB; Fitzgerald JB
Cancer Res; 2014 Dec; 74(23):7003-13. PubMed ID: 25273092
[TBL] [Abstract][Full Text] [Related]
12. Tissue penetration and activity of camptothecins in solid tumor xenografts.
Kyle AH; Baker JH; Gandolfo MJ; Reinsberg SA; Minchinton AI
Mol Cancer Ther; 2014 Nov; 13(11):2727-37. PubMed ID: 25143448
[TBL] [Abstract][Full Text] [Related]
13. Irinotecan/5-fluorouracil combination induces alterations in mitochondrial membrane potential and caspases on colon cancer cell lines.
Grivicich I; Regner A; da Rocha AB; Grass LB; Alves PA; Kayser GB; Schwartsmann G; Henriques JA
Oncol Res; 2005; 15(7-8):385-92. PubMed ID: 16491956
[TBL] [Abstract][Full Text] [Related]
14. Synergistic antitumor activity of capecitabine in combination with irinotecan.
Cao S; Durrani FA; Rustum YM
Clin Colorectal Cancer; 2005 Jan; 4(5):336-43. PubMed ID: 15663838
[TBL] [Abstract][Full Text] [Related]
15. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
[TBL] [Abstract][Full Text] [Related]
16. Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines.
Harris SM; Mistry P; Freathy C; Brown JL; Charlton PA
Br J Cancer; 2005 Feb; 92(4):722-8. PubMed ID: 15700035
[TBL] [Abstract][Full Text] [Related]
17. Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase.
Fukushima M; Sakamoto K; Ohshimo H; Nakagawa F; Taguchi T
Oncol Rep; 2010 Oct; 24(4):835-42. PubMed ID: 20811661
[TBL] [Abstract][Full Text] [Related]
18. in vitro synergistic antitumor activity of a combination of 5-fluorouracil and irinotecan in human colon cancer.
Inoue Y; Tanaka K; Hiro J; Yoshiyama S; Toiyama Y; Eguchi T; Miki C; Kusunoki M
Int J Oncol; 2006 Feb; 28(2):479-86. PubMed ID: 16391804
[TBL] [Abstract][Full Text] [Related]
19. Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer.
Messerer CL; Ramsay EC; Waterhouse D; Ng R; Simms EM; Harasym N; Tardi P; Mayer LD; Bally MB
Clin Cancer Res; 2004 Oct; 10(19):6638-49. PubMed ID: 15475454
[TBL] [Abstract][Full Text] [Related]
20. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.
Prewett MC; Hooper AT; Bassi R; Ellis LM; Waksal HW; Hicklin DJ
Clin Cancer Res; 2002 May; 8(5):994-1003. PubMed ID: 12006511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]